Business
Jan 24, 2026
Amyloidosis Market Global Outlook, Country Deep-Dives & Strategic Opportunities (2024-2033) Market size (2024): USD 1.2 billion · Forecast (2033): 1.20 Billion…
Jan 16, 2026
A new study published in Open Heart provided up-to-date data on the epidemiology of amyloid transthyretin (ATTR) amyloidosis in the US. “Our findings…
Jan 14, 2026
AbstractAmyloidosis is a group of disorders caused by extracellular deposition of insoluble fibrillar proteins, leading to progressive organ dysfunction. Cardiac…
Jan 12, 2026
Not intended for UK MediaBayer bolsters development portfolio by acquisition of two investigational imaging agents (AT-01 and AT-05) from Attralus, Inc. to advance…
Jan 06, 2026
AbstractBackgroundAcquired transthyretin (ATTR) amyloidosis is increasingly reported among domino liver transplantation (DLT) recipients who receive livers from…
Jan 05, 2026
Accurate differentiation between light-chain (AL) amyloidosis and transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) is critical for effective patient…
Dec 31, 2025
– NXC-201 demonstrated a complete response (CR) rate of 75% (15/20) (at s/u IFE(-) level) by independent review committee –– In four out of five pending patients,…
Mar 20, 2025
Advancements in RNAi Therapeutics | 2024-2025 Update for Investors in Hospitals and HealthcareRNA interference (RNAi) therapeutics have garnered significant…
Feb 25, 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, is hosting an R&D Day today in New York…
Feb 25, 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, is hosting an R&D Day today in New York…